Disparate kinetics of viable virus shedding in immunocompromised patients: SARS-CoV-2 versus influenza virus – a prospective real-world cohort study.

Disparate kinetics of viable virus shedding in immunocompromised patients: SARS-CoV-2 versus influenza virus – a prospective real-world cohort study.

Publication date: Sep 15, 2025

There are limited data comparing viral shedding between influenza and SARS-CoV-2 in immunocompromised patients. We prospectively enrolled 70 SARS-CoV-2 and 16 influenza patients, with 48 SARS-CoV-2 patients matched to 16 influenza patients by propensity score. Weekly-collected respiratory samples were subjected to viral culture and antigen testing. In matched cohorts, the time to culture-confirmed viral clearance was shorter for influenza than SARS-CoV-2 (median, 4. 5 vs. 29 days; adjusted Hazard Ratio [aHR] 27. 5; P

Concepts Keywords
Immunocompromised Immunoassay
Influenza Influenza
Viral SARS-CoV-2
Weekly viral shedding
virus culture

Semantics

Type Source Name
disease MESH immunocompromised patients
disease MESH virus shedding
disease MESH influenza

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *